CorMedix (CRMD) News Today $7.93 -0.25 (-3.06%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Barclays PLC Sells 84,122 Shares of CorMedix Inc. (NASDAQ:CRMD)Barclays PLC reduced its stake in CorMedix Inc. (NASDAQ:CRMD - Free Report) by 51.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,870 shares of the company's stock after selling 84,122 shares during the perJanuary 2, 2025 | marketbeat.comCorMedix Inc. (NASDAQ:CRMD) Receives Average Rating of "Buy" from AnalystsShares of CorMedix Inc. (NASDAQ:CRMD - Get Free Report) have earned an average rating of "Buy" from the five ratings firms that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among anDecember 22, 2024 | marketbeat.comCorMedix's SWOT analysis: defencath launch boosts stock amid expansion plansDecember 21, 2024 | uk.investing.comCorMedix (NASDAQ:CRMD) Stock Price Down 2.6% - Should You Sell?CorMedix (NASDAQ:CRMD) Stock Price Down 2.6% - Should You Sell?December 20, 2024 | marketbeat.comCorMedix price target raised to $12 from $11 at RBC CapitalDecember 20, 2024 | markets.businessinsider.comCorMedix (NASDAQ:CRMD) Stock Price Up 5.9% Following Analyst UpgradeCorMedix (NASDAQ:CRMD) Stock Price Up 5.9% After Analyst UpgradeDecember 19, 2024 | marketbeat.comCorMedix (NASDAQ:CRMD) Price Target Raised to $12.00Royal Bank of Canada lifted their price objective on CorMedix from $11.00 to $12.00 and gave the stock an "outperform" rating in a report on Thursday.December 19, 2024 | marketbeat.comCorMedix Inc. Added to Nasdaq Biotechnology IndexDecember 19, 2024 | globenewswire.comWellington Management Group LLP Acquires 102,527 Shares of CorMedix Inc. (NASDAQ:CRMD)Wellington Management Group LLP grew its holdings in CorMedix Inc. (NASDAQ:CRMD - Free Report) by 130.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 180,948 shares of the company's stock after purchasing an additional 102,527 shares duringDecember 19, 2024 | marketbeat.comIs CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks?December 19, 2024 | insidermonkey.comErin Mistry Acquires 1,500 Shares of CorMedix Inc. (NASDAQ:CRMD) StockDecember 14, 2024 | insidertrades.comCorMedix Inc. (NASDAQ:CRMD) EVP Purchases $14,985.00 in StockCorMedix Inc. (NASDAQ:CRMD - Get Free Report) EVP Erin Mistry purchased 1,500 shares of the firm's stock in a transaction that occurred on Thursday, October 31st. The stock was purchased at an average price of $9.99 per share, with a total value of $14,985.00. Following the completion of the purchase, the executive vice president now directly owns 52,011 shares of the company's stock, valued at approximately $519,589.89. This represents a 2.97 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.December 13, 2024 | marketbeat.comParallax Volatility Advisers L.P. Buys New Shares in CorMedix Inc. (NASDAQ:CRMD)Parallax Volatility Advisers L.P. purchased a new position in shares of CorMedix Inc. (NASDAQ:CRMD - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 80,143 shares of the company's stock, valued at approximateDecember 7, 2024 | marketbeat.comCorMedix Inc. (NASDAQ:CRMD) Given Average Recommendation of "Buy" by BrokeragesShares of CorMedix Inc. (NASDAQ:CRMD - Get Free Report) have earned a consensus recommendation of "Buy" from the five brokerages that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target amNovember 27, 2024 | marketbeat.comCorMedix supports CMS policy updatesNovember 26, 2024 | markets.businessinsider.comCorMedix Set for Market Growth with Policy Changes and Strategic Partnerships Boosting DefenCath AdoptionNovember 26, 2024 | markets.businessinsider.comCorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug ProductsNovember 26, 2024 | globenewswire.comCorMedix Inc. (NASDAQ:CRMD) EVP Elizabeth Hurlburt Sells 140,027 SharesNovember 19, 2024 | insidertrades.comCorMedix Inc. (NASDAQ:CRMD) Short Interest Down 20.1% in OctoberCorMedix Inc. (NASDAQ:CRMD - Get Free Report) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 6,280,000 shares, a decline of 20.1% from the October 15th total of 7,860,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 5.4 days.November 15, 2024 | marketbeat.comCorMedix (NASDAQ:CRMD) Stock Price Up 8.9% - Should You Buy?CorMedix (NASDAQ:CRMD) Trading 8.9% Higher - Here's What HappenedNovember 8, 2024 | marketbeat.comCorMedix (NASDAQ:CRMD) Upgraded to Sell at StockNews.comStockNews.com raised CorMedix to a "sell" rating in a research note on Friday.November 8, 2024 | marketbeat.comCorMedix Inc. to Participate in the Truist Securities BioPharma SymposiumNovember 4, 2024 | globenewswire.comRainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More OptimisticNovember 4, 2024 | finance.yahoo.comCorMedix Inc. (NASDAQ:CRMD) Receives Average Recommendation of "Buy" from BrokeragesCorMedix Inc. (NASDAQ:CRMD - Get Free Report) has earned an average rating of "Buy" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analyNovember 2, 2024 | marketbeat.comWhile shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunateNovember 1, 2024 | finance.yahoo.comCormedix (CRMD) Gets a Buy from RBC CapitalOctober 31, 2024 | markets.businessinsider.comCorMedix (NASDAQ:CRMD) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPSCorMedix (NASDAQ:CRMD - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The firm had revenue of $11.46 million during the quarter, compared to analysts' expectations of $11.00 million. During the same period last year, the business posted ($0.17) EPS.October 31, 2024 | marketbeat.comCorMedix Inc. (NASDAQ:CRMD) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | insidermonkey.comCorMedix (NASDAQ:CRMD) Price Target Raised to $18.00Needham & Company LLC lifted their price target on shares of CorMedix from $10.00 to $18.00 and gave the stock a "buy" rating in a research note on Thursday.October 31, 2024 | marketbeat.comCorMedix Inc. Reports Q3 2024 Financial ResultsOctober 31, 2024 | markets.businessinsider.comCormedix’s Growth Prospects Justify Buy Rating Despite Market PressuresOctober 31, 2024 | markets.businessinsider.comCormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising ExpensesOctober 31, 2024 | finance.yahoo.comCorMedix (CRMD) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | msn.comStrong Buy Recommendation for Cormedix Amid DefenCath’s Promising Market Trajectory and Strategic PartnershipsOctober 30, 2024 | markets.businessinsider.comCorMedix, Inc.: CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business UpdateOctober 30, 2024 | finanznachrichten.deCorMedix (NASDAQ:CRMD) Shares Gap Down - Should You Sell?CorMedix (NASDAQ:CRMD) Shares Gap Down - Time to Sell?October 30, 2024 | marketbeat.comCorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business UpdateOctober 30, 2024 | globenewswire.comEarnings Preview For CormedixOctober 29, 2024 | benzinga.comCormedix Inc (CRMD) Q3 2024 Earnings Report Preview: What To Look ForOctober 29, 2024 | finance.yahoo.comCorMedix (NASDAQ:CRMD) Sets New 12-Month High - Should You Buy?CorMedix (NASDAQ:CRMD) Reaches New 52-Week High - What's Next?October 28, 2024 | marketbeat.comCorMedix 2.0: New Leadership, New Approval, New FocusOctober 28, 2024 | seekingalpha.comCormedix (CRMD) Receives a Buy from Truist FinancialOctober 28, 2024 | markets.businessinsider.comCorMedix, Inc. (CRMD)October 25, 2024 | uk.finance.yahoo.comCorMedix announces new data at ASN Kidney Week 2024October 25, 2024 | markets.businessinsider.comCorMedix (NASDAQ:CRMD) Sees Strong Trading Volume - Still a Buy?CorMedix (NASDAQ:CRMD) Sees Unusually-High Trading Volume - Time to Buy?October 24, 2024 | marketbeat.comCorMedix (CRMD) Set to Announce Quarterly Earnings on WednesdayCorMedix (NASDAQ:CRMD) will be releasing earnings before the market opens on Wednesday, October 30, Zacks reports.October 24, 2024 | marketbeat.comCorMedix Inc. Announces New Data at ASN Kidney Week 2024October 24, 2024 | globenewswire.comCorMedix (NASDAQ:CRMD) Stock Price Up 3.3% After Analyst UpgradeCorMedix (NASDAQ:CRMD) Trading Up 3.3% Following Analyst UpgradeOctober 23, 2024 | marketbeat.comCorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024October 23, 2024 | globenewswire.comCorMedix price target raised to $17 from $12 at TruistOctober 22, 2024 | markets.businessinsider.com Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address CRMD Media Mentions By Week CRMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRMD News Sentiment▼1.850.84▲Average Medical News Sentiment CRMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRMD Articles This Week▼33▲CRMD Articles Average Week Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GLPG News IRON News AGIO News ARQT News XNCR News AMPH News INDV News EVO News TVTX News IMCR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRMD) was last updated on 1/6/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored$24 trillion tech spotted at Mar-a-Lago?President Trump’s Secret Service was recently spotted using an odd new technology at his home in Mar-a-Lago…Centurion Publishing | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRMD Stock Alerts